Eli Lilly and Co's obesity drug Zepbound led to greater weight loss than Novo Nordisk's Wegovy in a head-to-head Phase 3b ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

People taking Eli Lilly and Co.'s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's ...

Novo Nordisk replaces CEO amid declining market share and falling stock. Eli Lilly has steadily gained market share against Novo's Wegovy which finds itself catching up. Roche, Amgen, Merck ...

Stocktwits - Eli Lilly (NYSE:LLY) and Co’s obesity drug Zepbound led to greater weight loss than Novo Nordisk (CSE:NOVOb)’s Wegovy in a head-to-head Phase 3b trial, according to data published in The ...

President Trump said he would sign an executive order to base U.S. drug prices on what other countries pay — usually far less ...

Eli Lilly said its Zepbound obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in a head-to-head study of the two drugs.

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Eli Lilly has decided to wait for the readout of the second of its two phase 3 trials for tirzepatide ... start a rolling application for the drug in obesity this year that will complete in ...